Pipeline

Le pipeline de Nosopharm est focalisé sur le traitement des maladies infectieuses, en particulier dans le contexte d’augmentation de l’antibiorésistance.

Nos principaux programmes de R&D s’appuient sur notre expertise unique dans l’exploitation pharmacologique des bactéries Photorhabdus et Xenorhabdus.

PIPELINE_FR (1)
 Enterobacteriaceae

The main hospital pathogens of the Enterobacteriaceae family are the bacteria Escherichia coli and Klebsiella pneumoniae. These are detected in 20% of the hospital-acquired infections in the EU and the US (Sources: ECDC, CDC). The main antibiotic classes used to treat them are cephalosporins, aminoglycosides, fluoroquinolones and carbapenems. The multidrug resistance rates of these pathogens to these various classes have reached some particularly troubling thresholds. In the EU 19% of the K. pneumoniae strains present combined resistances to cephalosporins, aminoglycosides and fluoroquinolones. In Greece and Italy, 62% and 34% respectively, of the strains of this same pathogen are resistant to carbapenems, considered as a last-resort antibiotic class (Source: ECDC). Carbapenem-resistant Enterobacteriaceae were given a critical priority by the WHO for the R&D of new antibiotics.
Enterobacteriaceae

The main hospital pathogens of the Enterobacteriaceae family are the bacteria Escherichia coli and Klebsiella pneumoniae. These are detected in 20% of the hospital-acquired infections in the EU and the US (Sources: ECDC, CDC). The main antibiotic classes used to treat them are cephalosporins, aminoglycosides, fluoroquinolones and carbapenems. The multidrug resistance rates of these pathogens to these various classes have reached some particularly troubling thresholds. In the EU 19% of the K. pneumoniae strains present combined resistances to cephalosporins, aminoglycosides and fluoroquinolones. In Greece and Italy, 62% and 34% respectively, of the strains of this same pathogen are resistant to carbapenems, considered as a last-resort antibiotic class (Source: ECDC). Carbapenem-resistant Enterobacteriaceae were given a critical priority by the WHO for the R&D of new antibiotics.
P. aeruginosa

The hospital pathogen Pseudomonas aeruginosa is involved in about 10% of the hospital-acquired infections in the EU and the US, with a strong incidence in pneumonia (Sources: ECDC, CDC). The main antibiotic classes used to treat it are piperacillin (alone or in combination with tazobactam), ceftazidime, aminoglycosides, fluoroquinolones and carbapenems. The multidrug resistance rates of this pathogen to these various classes have also reached some particularly troubling levels. In the EU, 13% of the P. aeruginosa strains present combined resistances to three classes at least. Carbapenem-resistant Pseudomonas aeruginosa was given a critical priority for the R&D of new antibiotics by the WHO.
Candida

The main fungal hospital pathogens are the Candida species which are detected in 6% of the hospital-acquired infections in the EU and the US (Sources: ECDC, CDC). Very few antifungal drug classes are available to treat these infections: the azoles, the echinocandins, the polyenes and flucytosine. This is of particular concern since some multidrug-resistant Candida species are rapidly emerging, such as Candida glabrata and Candida auris (Source: CDC)

NOSO-502

NOSO-502 EST LE PREMIER CANDIDAT-MEDICAMENT AU STADE CLINIQUE DE NOSOPHARM ISSU DE LA NOUVELLE CLASSE ANTIBIOTIQUE DES ODILHORABDINES, DECOUVERT PAR LA SOCIETE A PARTIR DE LA BACTERIE XENORHABDUS.

NOSO-502 est destiné au traitement des principales infections nosocomiales causées par les bactéries multi-résistantes Escherichia coli, Klebsiella pneumoniae et Enterobacter spp (BLSE, ERC).

NOSO-502 inhibe le ribosome bactérien à l’aide d’un nouveau mécanisme d’action. Il agit contre les Enterobacteriaceae, les Entérobactéries résistantes aux carbapénèmes (CRE), quel que soit leur profil de production de carbapénèmases. Ces agents pathogènes sont responsables d’infections nosocomiales graves et potentiellement mortelles. L’OMS a listé les Enterobactéries résistantes aux carbapénèmes dans les pathogènes à cibler en priorité pour la recherche et le développement de nouveaux antibiotiques, et le CDC (Centers for Disease Control and Prevention) dans les menaces urgentes en antibiorésistance.

Publications

NOSO-2G

NOSO-2G est un antibiotique de deuxième génération de la classe des Odilorhabdines, actuellement au stade préclinique précoce. Il agit contre les bactéries résistantes aux carbapénèmes Pseudomonas aeruginosa et Acinetobater baumannii.

Ces agents pathogènes sont responsables d’infections nosocomiales potentiellement mortelles. L’OMS a listé les Enterobactéries résistantes aux carbapénèmes comme prioritaires pour la recherche et le développement de nouveaux antibiotiques.

NOSO-2G est destiné au traitement des pneumonies nosocomiales et des pneumonies associées à la ventilation mécanique/assistée (HAP/VAP), y compris les infections dues à des agents pathogènes multirésistants.

Publications

Autres programmes de R&D

Nosopharm développe d’autres programmes de R&D dans le domaine des maladies infectieuses, issus de sa plateforme de découverte de médicaments basée sur Photorhabdus et Xenorhabdus. Des campagnes de screening sont en cours pour découvrir de nouvelles classes d’antifongiques pour le traitement de la candidose invasive, causée par des agents pathogènes multirésistants émergents tels que Candida auris et Candida glabrata.

The discovery and development of NOSO-502 and NOSO-2G have been funded in part with financial support from Bpifrance and Région Occitanie / Pyrénées-Méditerranée under grant agreement A1010014J, from Direction Générale de l’Armement (DGA), Ministère des Armées, et Direction Générale des Entreprises, Ministère de l’Economie, des Finances et de la Relance under grant agreement RAPID 122906117, from the Innovative Medicines Initiative Joint Undertaking under grant agreement No 115583, resources of which are comprised of financial contributions from the European Union’s seventh framework program (FP7/2007-2013) and EFPIA companies’ in-kind contribution, from Bpifrance under agreement DOS0063094/00, and from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853979: “GNA NOW: Gram-Negative Antibacterials NOW”, the JU receiving support from the European Union’s Horizon 2020 research and innovation programme and the EFPIA company Evotec’s in-kind contribution and being part of the AMR Accelerator.